EWTX

Edgewise Therapeutics, Inc.

16.61 USD
+0.28 (+1.71%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Edgewise Therapeutics, Inc. stock is down -13.4% since 30 days ago. The next earnings date is May 9, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 3 March’s closed higher than February.

About Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc. develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy.